Renalytix Plc Overview
Pro stress-test →Renalytix is an AI-enabled in vitro diagnostics company focused on kidney disease management. The company's flagship product, KidneyIntelX, uses artificial intelligence, blood-based biomarkers, genetics, and patient health data to predict rapid kidney function decline in patients with type 2 diabetes and chronic kidney disease.
Strategic Profile
Pro stress-test →Renalytix is the global founder and leader in bioprognosis for kidney health, holding FDA authorization for its KidneyIntelX test with broad insurance coverage. The company leverages strategic partnerships with major pharmaceutical companies like AstraZeneca and healthcare systems to expand adoption and clinical validation of its prognostic platform.
Competitive Landscape
Pro stress-test →Renalytix operates in the AI-enabled diagnostics space competing against traditional diagnostic providers and emerging AI health tech companies. The company's niche focus on kidney disease prognosis provides differentiation, though it faces broader competition from large diagnostic lab services (LabCorp, Quest Diagnostics) and specialized kidney health platforms. Market adoption depends on physician education and demonstrated clinical outcomes value.
Industry Context
Renalytix Plc operates in AI-Enabled In Vitro Diagnostics and Laboratory Services.
Key facts
Founded: 2018 · Headquarters: London, UK · Employees: 46 · Revenue: Unknown · Market cap: Unknown